Tizanidine and Flexeril (cyclobenzaprine) are not the same medication. They are two distinct drugs with different chemical structures, different mechanisms of action, and somewhat different uses, though both fall under the broad category of muscle relaxants. If you’ve been prescribed one and are wondering whether you can swap it for the other, the short answer is no, not without your prescriber’s involvement. Here’s what actually sets them apart.
How Each Drug Works
Tizanidine (brand name Zanaflex) works in the brain and spinal cord by activating receptors that dial down nerve signals responsible for muscle tightness. It acts centrally to reduce the excitability of spinal neurons, which is why it’s particularly useful for spasticity, the kind of persistent, involuntary muscle stiffness seen in conditions like multiple sclerosis and spinal cord injuries.
Cyclobenzaprine (brand name Flexeril) is structurally related to tricyclic antidepressants. It also acts in the central nervous system, but through a different pathway. It reduces muscle spasm by influencing brain-stem activity rather than acting directly on the spinal cord circuits the way tizanidine does. This makes it better suited for short-term relief of acute musculoskeletal pain, like a pulled back muscle or neck strain.
Different Conditions, Different Roles
Muscle relaxants are formally divided into two categories: antispastic agents (for neurological conditions like cerebral palsy and multiple sclerosis) and antispasmodic agents (for everyday musculoskeletal injuries). Cyclobenzaprine sits squarely in the antispasmodic category. Tizanidine is more versatile. It’s classified as both an antispastic and an antispasmodic agent, meaning it can be prescribed for neurological spasticity as well as for general muscle pain and tightness.
In practice, this means cyclobenzaprine is the one you’re more likely to receive after tweaking your back at the gym. Tizanidine is more often prescribed for people living with ongoing neurological conditions, though it’s also used for musculoskeletal problems when a prescriber prefers its profile.
Side Effects and How They Differ
Both drugs cause drowsiness and dizziness, which is typical of centrally acting muscle relaxants. Beyond that shared trait, their risk profiles diverge in important ways.
Tizanidine carries a specific risk to the liver. In clinical studies, roughly 5% of patients on tizanidine developed liver enzyme elevations more than three times the normal upper limit, compared to just 0.4% of patients on placebo. Because of this, liver function tests are recommended at the start of treatment and periodically afterward. Signs of liver trouble to watch for include unexplained fatigue, nausea, loss of appetite, dark urine, or yellowing of the skin or eyes.
Cyclobenzaprine’s risks lean toward the heart. Because of its structural similarity to tricyclic antidepressants, it can affect heart rhythm. It has been associated with rapid heartbeat, arrhythmias, heart block, and changes to the electrical activity of the heart. For this reason, cyclobenzaprine is contraindicated in people recovering from a heart attack and in those with heart failure, arrhythmias, heart block, or an overactive thyroid. These cardiac events occur in fewer than 1% of patients, but the risk is real enough that people with existing heart conditions are typically steered toward a different option.
Cyclobenzaprine also has stronger anticholinergic effects, the kind of side effects you’d associate with older antihistamines: dry mouth, blurred vision, constipation, and urinary retention. Tizanidine can cause dry mouth too, but its anticholinergic burden is generally lower.
Drug Interaction Risks
Each medication has a distinct set of dangerous interactions. Tizanidine is broken down in the liver by a specific enzyme pathway. Certain antibiotics (particularly fluoroquinolones like ciprofloxacin), the antidepressant fluvoxamine, and other drugs that inhibit this same enzyme can cause tizanidine levels to spike dramatically, leading to severe drops in blood pressure, excessive sedation, or both. If you’re taking tizanidine and get prescribed an antibiotic, this is something to flag.
Cyclobenzaprine’s biggest interaction concern involves serotonin. Because of its chemical kinship with tricyclic antidepressants, combining it with SSRIs, SNRIs, tramadol, or other serotonin-boosting medications raises the risk of serotonin syndrome, a potentially dangerous condition marked by agitation, rapid heart rate, high body temperature, and muscle rigidity. Cyclobenzaprine should also not be taken with or within two weeks of MAO inhibitors.
Safety in Older Adults
This is one of the clearest differences between the two. The American Geriatrics Society’s Beers Criteria, a widely used guide for identifying medications that are potentially inappropriate in older adults, lists cyclobenzaprine as a drug to avoid in this population. The reasoning: muscle relaxants like cyclobenzaprine are poorly tolerated by older adults because of their anticholinergic side effects, sedation, and increased fracture risk. Their effectiveness at doses older adults can actually tolerate is also questionable.
Tizanidine, by contrast, is explicitly excluded from that same warning. The Beers Criteria notes that tizanidine, along with baclofen, is typically used for spasticity management and does not fall under the same “avoid” recommendation. That said, the document acknowledges tizanidine can still cause substantial side effects in any age group, so it’s not risk-free for older adults either.
Duration of Use
Cyclobenzaprine is generally intended for short-term use, typically two to three weeks. It’s designed to get you through the acute phase of a muscle injury alongside rest and physical therapy, not to be taken indefinitely. Tizanidine, on the other hand, is often prescribed for longer periods because the conditions it treats, like spasticity from multiple sclerosis or spinal cord injury, are chronic. This longer treatment window is one reason liver monitoring matters with tizanidine.
Can One Replace the Other?
Sometimes, but not automatically. For acute musculoskeletal pain, both drugs can reduce muscle spasm and improve comfort. A prescriber might choose one over the other based on your health history. Someone with a heart condition would generally be a poor candidate for cyclobenzaprine. Someone with liver disease would likely be steered away from tizanidine. An older adult might do better on tizanidine given the Beers Criteria guidance, though careful monitoring would still apply.
For spasticity caused by a neurological condition, tizanidine has a role that cyclobenzaprine does not fill. Cyclobenzaprine is not classified as an antispastic agent and is not typically prescribed for conditions like multiple sclerosis or cerebral palsy. If you’re managing spasticity and considering a switch, tizanidine and baclofen are the more appropriate options in that category.